Endocrine research
Ipamorelin vs CJC-1295
Selective GHRP research beside extended GHRH analogue literature.
Overview
This comparison separates Ipamorelin and CJC-1295 for laboratory reference—not product selection.
Ipamorelin: Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produc…
CJC-1295: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this versio…
Key differences
- Both appear in Tissue repair & recovery literature, but mechanistic framing differs.
- The useful distinction is research question and receptor context—not relative potency or practical ranking.
Mechanistic differences
Ipamorelin: Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile a…
CJC-1295: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 w…
Pharmacology
Ipamorelin: Pharmacokinetic detail should be read from primary literature.
CJC-1295: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 w…
Research focus
Ipamorelin: GLP-1 & metabolic: Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety…
CJC-1295: Tissue repair & recovery: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. U…
At a glance
Practical differentiation
- AXIOM does not provide dosing, administration, or protocol guidance.
- Catalogue links appear only where AXIOM lists a research-use product.
- Reference-only compounds remain comparison terms without implying availability.
References
- pubmed.ncbi.nlm.nih.gov/9849822/
- pubmed.ncbi.nlm.nih.gov/25331030/
- pubmed.ncbi.nlm.nih.gov/10496658/
- pubmed.ncbi.nlm.nih.gov/10373343/
- pubmed.ncbi.nlm.nih.gov/11735244/
- pubmed.ncbi.nlm.nih.gov/16352683/
- pubmed.ncbi.nlm.nih.gov/17018654/
- pubmed.ncbi.nlm.nih.gov/15817669/
FAQ
Does this page recommend Ipamorelin or CJC-1295?
No. It is an editorial comparison for research context only.
Does AXIOM provide protocol guidance?
No. Protocol and dosing decisions belong with qualified laboratory teams and source literature.